2026-10-15T12:09:23Z https://data.mendeley.com/oai

oai:data.mendeley.com/98c99dcvtt.2 2022-12-20T11:29:42Z

Asdourian, Maria Association between serum LDH and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma: supplemental materials Mendeley Data The first file details the methodological approach and results of survival analysis using Cox proportional hazards regression modeling to examine the relationship between LDH level and progression-free (PFS) or overall survival (OS) among all patients in our cohort. Results demonstrated that elevated serum LDH at >3 months after ICI initiation was significantly associated with worse PFS (HR: 2.81; p<0.001) and OS (HR: 4.77; p<0.001). There were no significant relationships between PFS or OS when examining LDH level at baseline. These results suggest that having an elevated LDH at the >3 month time point is representative of metastatic burden and may be more of a marker for lack of response to ICIs rather than a predictor of survival outcomes. It is possible that our smaller sample size was insufficiently powered to detect survival outcomes but more appropriate for detecting cutaneous immune-related adverse event (cirAE) outcomes. The second file includes Supplemental Table 1. Dermatological Disease Adverse Event Melanoma Lactate Dehydrogenase Immune Checkpoint Blockade Otto, Tracey Jacoby, Ted Shah, Nishi Blum, Steven Reynolds, Kerry Semenov, Yevgeniy Lawrence, Donald Sullivan, Ryan Boland, Genevieve Villani, Alexandra-Chloé Chen, Steven Dataset doi:10.17632/98c99dcvtt.2 oai:data.mendeley.com/98c99dcvtt.2 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/98c99dcvtt 2022-12-20T11:29:42Z